Indapamide
Quick Facts
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Hypertension — to lower blood pressure | Adults | Monotherapy or in combination with other antihypertensives | FDA Approved |
| Salt and fluid retention associated with congestive heart failure | Adults | Adjunctive — typically combined with disease-specific therapy | FDA Approved |
Indapamide is a thiazide-like diuretic of the indoline class. It is structurally distinct from both the benzothiadiazine thiazides (e.g., hydrochlorothiazide) and the chlorthalidone-type sulfonamides, sharing only the sulfamoyl-chlorobenzamide moiety necessary for action at the distal convoluted tubule. Indapamide is unusual among thiazide-class agents in that it is extensively metabolized rather than primarily excreted unchanged (only ~7% appears as unchanged drug in urine), and it has no clinically significant carbonic-anhydrase inhibitory activity. The narrower US labeling — hypertension and CHF-associated edema only — reflects the fact that indapamide entered the US market later and was approved for fewer indications than the older thiazides.
Indapamide is the active diuretic in three landmark cardiovascular outcome trials, all using the European 1.5 mg sustained-release formulation: HYVET (2008, NEJM) in patients ≥80 years showed indapamide-based therapy reduced fatal stroke, all-cause mortality, and heart failure; PROGRESS (2001, Lancet) showed perindopril/indapamide reduced recurrent stroke; and ADVANCE (2007, Lancet) showed perindopril/indapamide reduced major macrovascular and microvascular events in type 2 diabetes. These trials are the principal evidence base placing indapamide alongside chlorthalidone as the preferred thiazide-class agents in major hypertension guidelines (2017 ACC/AHA, 2023 ESH).
Calcium nephrolithiasis prevention — like other thiazide-class agents, indapamide reduces urinary calcium excretion. Less commonly prescribed for this indication than HCTZ or chlorthalidone but reasonable when those are not tolerated. Evidence: moderate (extrapolated class effect).
Resistant hypertension — indapamide’s prolonged action and potent BP lowering make it a useful add-on or substitute for HCTZ in resistant cases, especially with concurrent ACEi or ARB. Evidence: moderate.
Nephrogenic diabetes insipidus — paradoxical antidiuretic effect via volume contraction. Less commonly used than HCTZ for this indication. Evidence: low (small series).
Stroke secondary prevention — although not in current FDA labeling, the combination of perindopril plus indapamide has Class I guideline-level evidence (PROGRESS trial) for secondary stroke prevention. Evidence: high (RCT).
Dosing
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Hypertension — adult (US generic 1.25/2.5 mg IR) | 1.25 mg once daily in the morning | 1.25–2.5 mg/day | 5 mg once daily | If response inadequate after 4 weeks, increase to 2.5 mg; after another 4 weeks, may increase to 5 mg Doses ≥5 mg add little BP benefit but markedly increase hypokalemia (61% at 5 mg vs 20% at 1.25 mg per FDA label) |
| Hypertension — adult (EU/UK 1.5 mg SR) | 1.5 mg once daily in the morning | 1.5 mg/day | 1.5 mg/day (no titration) | Sustained-release formulation used in HYVET, PROGRESS, ADVANCE. Not available in the US If BP control inadequate, add a second class rather than increasing dose |
| Edema of congestive heart failure — adult | 2.5 mg once daily in the morning | 2.5–5 mg/day | 5 mg once daily | If response inadequate after 1 week, increase to 5 mg Doses >5 mg do not provide additional benefit but increase hypokalemia |
| Resistant hypertension (off-label add-on) | 1.25 mg once daily | 1.25–2.5 mg/day | 2.5 mg/day | Can replace HCTZ in resistant HTN regimens. Combine with ACEi/ARB to mitigate hypokalemia |
| Calcium nephrolithiasis prevention (off-label) | 1.25 mg once daily | 1.25–2.5 mg/day | 2.5 mg/day | Less RCT evidence than HCTZ or chlorthalidone for stones; combine with adequate fluid intake (>2 L/day) |
Renal Considerations
| Renal Function | Approach |
|---|---|
| eGFR ≥45 mL/min/1.73 m² | Standard dosing |
| eGFR 30–44 mL/min/1.73 m² | Use with caution per FDA label; reduced diuretic effect (the FDA label notes that diuretic effects decline as renal function decreases) but BP-lowering effect partially preserved. Monitor kidney function more frequently |
| eGFR <30 mL/min/1.73 m² | Indapamide may exacerbate or precipitate azotemia per FDA label; loop diuretic generally preferred for edema. Per the FDA label, “if progressive renal impairment is observed, withholding or discontinuing diuretic therapy should be considered” |
| Anuria | Contraindicated per FDA labeling |
The FDA indapamide label does not specify a numerical eGFR cutoff; cutoffs above are clinical-practice guidance.
Hepatic Adjustment
The FDA label does not provide a numerical dose adjustment for hepatic impairment but warns that indapamide should be used with caution in patients with impaired hepatic function or progressive liver disease, since minor alterations of fluid and electrolyte balance may precipitate hepatic coma. Initiate at the lowest effective dose (1.25 mg) and avoid abrupt fluid or electrolyte shifts in cirrhosis.
Geriatric, Pregnancy, Lactation & Pediatric
Per the FDA label, dose selection in older adults should begin at the low end of the dosing range, given the higher likelihood of decreased renal, hepatic, or cardiac function. Severe hyponatremia accompanied by hypokalemia has been reported with recommended doses of indapamide, primarily in elderly females — this is a specific labeled warning. Pregnancy: use only if clearly needed; routine use of diuretics in healthy pregnant women is inappropriate per FDA label, with risks including fetal/neonatal jaundice, thrombocytopenia, and electrolyte imbalances. Lactation: it is not known whether indapamide is excreted in human milk; the FDA label states that if treatment is deemed essential, the patient should stop nursing. Pediatric: safety and effectiveness have not been established (in contrast to hydrochlorothiazide, which is FDA-approved for pediatric use in the Inzirqo formulation).
The FDA label recommends starting at the lowest possible dose (1.25 mg) because hypokalemia and hyponatremia are starkly dose-related. In controlled trials of 6–8 weeks, hypokalemia (K⁺ <3.4 mEq/L) occurred in 20% at 1.25 mg, 61% at 5 mg, and 80% at 10 mg. Severe hyponatremia (Na⁺ <125 mEq/L) was not observed in trials with the 1.25 mg dose but was identified in pharmacoepidemiology studies of 2.5 mg and 5 mg use, predominantly in older women. Practical implication: stay at 1.25 mg unless BP demands escalation, and add an ACEi/ARB or second class rather than titrating to 5 mg. The European 1.5 mg SR (the formulation used in HYVET, PROGRESS, ADVANCE) provides similar BP control with less hypokalemia by smoothing the peak — but it is not available in the US.
Pharmacology
Mechanism of Action
Indapamide is the prototype of the indoline class of antihypertensive/diuretic agents. Like other thiazide-class diuretics, it inhibits the thiazide-sensitive sodium-chloride cotransporter (NCC; encoded by SLC12A3) in the distal convoluted tubule, increasing urinary excretion of sodium and chloride. The resulting reduction in extracellular fluid volume drives the early antihypertensive effect. Unlike older thiazides, indapamide also has a direct vasorelaxant effect mediated by reduced vascular smooth-muscle responsiveness to vasoconstrictors and possibly inhibition of calcium influx into vascular smooth muscle — features that may explain why its blood-pressure effect is preserved at doses below those producing maximum natriuresis. The FDA label notes that at antihypertensive doses (1.25–5 mg), indapamide has no appreciable cardiac inotropic or chronotropic effect, and chronic use does not significantly affect glomerular filtration rate or renal plasma flow.
Like other thiazide-class agents, indapamide decreases urinary calcium excretion (a useful effect in calcium nephrolithiasis), increases urinary potassium and magnesium loss, and reduces uric acid clearance.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Rapid and essentially complete; Tmax ~2 h (IR formulation); Tmax ~12 h (SR formulation); peak whole-blood concentrations ~115 ng/mL after 2.5 mg, ~260 ng/mL after 5 mg per FDA label; food does not meaningfully affect AUC | Take in the morning to limit nocturia; can be taken with or without food |
| Distribution | Plasma protein binding 71–79%; preferentially taken up by erythrocytes (whole-blood/plasma ratio ~6:1 at peak, declining to 3.5:1 at 8 h); crosses placental barrier; excretion in human milk unknown | The high erythrocyte partitioning explains the long terminal half-life and the practical advantage of once-daily dosing despite a relatively short plasma half-life |
| Metabolism | Extensively hepatically metabolized; only ~7% recovered as unchanged drug in urine over 48 h; multiple inactive metabolites | Distinguishes indapamide from chlorthalidone and HCTZ (which are eliminated largely unchanged in urine). Hepatic dysfunction may affect clearance |
| Elimination | Whole-blood t½ ~14 h; terminal t½ of total radioactivity ~26 h per FDA label; ≥70% excreted by kidneys (unchanged drug + metabolites), ~23% via biliary/GI route | Once-daily dosing produces 24-hour BP coverage. Combined renal and biliary elimination provides some buffering against accumulation in mild renal impairment |
Side Effects
The FDA prescribing information for indapamide includes specific quantitative incidence data from the registration trials at the 1.25 mg, 2.5 mg, and 5 mg doses — unusual for a thiazide-class agent. Frequencies in the tables below are taken directly from the FDA label where available, and from the named landmark trials (HYVET, PROGRESS) and pharmacoepidemiology analyses for events not quantified in the label. Most adverse effects are markedly dose-related, supporting the labeled recommendation to start at 1.25 mg and stay at the lowest effective dose.
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Hypokalemia (K⁺ <3.4 mEq/L) — laboratory finding | 20% at 1.25 mg; 61% at 5 mg; 80% at 10 mg (FDA label) | Strongly dose-related (FDA label). About 40% of those with low K⁺ at 1.25 mg returned to normal without intervention |
| Mean serum potassium decrease | −0.28 mEq/L at 1.25 mg; −0.61 at 5 mg; −0.76 at 10 mg (FDA label) | Quantitative effect from registration trials; explains the value of 1.25 mg starting dose |
| Headache | ≥5% at 1.25 mg (FDA label) | FDA Table 1 of registration trials; usually mild and transient |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Symptomatic hypokalemia | 2% at 1.25 mg; 3% at 2.5 mg; 7% at 5 mg (FDA label) | Far less common than the laboratory finding. Symptoms include weakness, cramps, palpitations |
| Dizziness | ≥5% at 1.25 mg (FDA label) | FDA Table 1. May reflect early volume contraction or orthostasis |
| Infection / flu-like symptoms / rhinitis | ≥5% (FDA label, all 1.25 mg) | Likely background incidence captured in registration trials; not clearly drug-related |
| Back pain / general pain | ≥5% at 1.25 mg (FDA label) | Not clearly drug-related; reported in placebo-controlled studies |
| Mean serum sodium decrease | −0.63 mEq/L at 1.25 mg (FDA label) | Mild population-mean shift; clinically significant hyponatremia is much less common at 1.25 mg |
| Mean serum uric acid increase | +0.69 mg/dL at 1.25 mg; +1 mg/dL at 2.5–5 mg (FDA label) | Periodic uric acid monitoring is recommended per FDA label |
| Mean glucose increase | +6.47 mg/dL at 1.25 mg (FDA label) | Not considered clinically significant in registration trials but supports periodic glucose monitoring |
| Fatigue, asthenia, lethargy | ≥5% at 2.5–5 mg (FDA Table 2) | More prominent at higher doses |
| Muscle cramps or numbness of extremities | ≥5% at 2.5–5 mg (FDA Table 2) | Often reflects hypokalemia or hypomagnesemia |
| Nervousness, anxiety, irritability | ≥5% at 2.5–5 mg (FDA Table 2) | Mostly reported in long-term controlled trials; mechanism unclear |
| Orthostatic hypotension | <5% (FDA Table 2) | More common in elderly and volume-depleted patients |
| Polyuria, nocturia, urinary frequency | <5% (FDA Table 2) | Pharmacologic effect; advise morning dosing |
| Erectile dysfunction / reduced libido | <5% (FDA Table 2) | Reported in long-term studies. Often improves with dose reduction or class switch |
| Rash, hives, pruritus | <5% (FDA Table 2) | Counsel sun protection; rare progression to severe cutaneous reactions warrants discontinuation |
| GI symptoms (anorexia, nausea, vomiting, cramping, diarrhea, constipation, gastric irritation) | <5% (FDA Table 2) | Persistent symptoms can compound volume depletion and electrolyte loss |
| Premature ventricular contractions, irregular heart beat, palpitations | <5% (FDA Table 2) | Often reflects underlying hypokalemia or hypomagnesemia rather than direct drug effect |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Severe hyponatremia (Na⁺ <125 mEq/L) — labeled warning | Not seen at 1.25 mg in trials; identified at 2.5 and 5 mg in pharmacoepidemiology, predominantly in elderly females | Days to weeks; spike in older women | Discontinue; correct sodium cautiously (≤8–10 mEq/L per 24 h) to avoid osmotic demyelination; do not rechallenge. Maintain at 1.25 mg dose where possible |
| Symptomatic hypokalemia (with ECG changes or muscle weakness) | 2–7% (dose-dependent per FDA label) | Days to weeks | Reduce dose, correct K⁺ and Mg, consider class switch or addition of K⁺-sparing partner. Especially important in patients on cardiac glycosides or with arrhythmias |
| Acute kidney injury / azotemia | Uncommon | Days to weeks; precipitated by intercurrent illness, NSAIDs, ACEi/ARB | Hold drug; address volume status, NSAIDs, contrast exposure. FDA label: if progressive renal impairment is observed, withholding or discontinuing should be considered |
| Acute angle-closure glaucoma / acute myopia / choroidal effusion | Rare (idiosyncratic, sulfonamide reaction; July 2020 postmarketing addition to label) | Hours to weeks of initiation | Discontinue immediately per FDA label; urgent ophthalmology review. Untreated angle-closure can cause permanent vision loss. Risk factors include sulfonamide or penicillin allergy |
| Severe hypersensitivity reactions (anaphylaxis, necrotizing angiitis/vasculitis, pneumonitis, respiratory distress) | Very rare (FDA label) | First dose to weeks | Permanent discontinuation; treat per anaphylaxis or organ-specific protocol |
| Severe cutaneous adverse reactions (Stevens-Johnson syndrome, erythema multiforme, bullous eruptions) | Very rare (FDA label) | Days to weeks | Permanent discontinuation; urgent dermatology / burn-unit referral; supportive care |
| Hepatotoxicity (intrahepatic cholestatic jaundice, hepatitis, abnormal LFTs) | Rare; reversible with discontinuation per FDA label | Variable | Discontinue; recheck LFTs; do not rechallenge |
| Pancreatitis | Rare (FDA label) | Variable; weeks to years | Discontinue; standard pancreatitis care; do not rechallenge |
| Blood dyscrasias (agranulocytosis, leukopenia, thrombocytopenia, aplastic anemia) | Very rare (FDA label) | Variable | Discontinue; hematology consultation; supportive care |
| Hepatic encephalopathy / hepatic coma (in cirrhosis) | Rare overall; meaningful in advanced cirrhosis | Days; precipitated by minor electrolyte shifts and volume contraction | FDA label warns to monitor fluid/electrolyte balance; hold drug if encephalopathy develops |
| Possible activation of systemic lupus erythematosus | Class effect; FDA label notes possibility should be considered with indapamide | Variable | Discontinue if lupus features develop or worsen; rheumatology referral |
Note on non-melanoma skin cancer: the August 2020 FDA labeling change adding NMSC risk to hydrochlorothiazide has not been extended to indapamide in current US FDA labels. Photosensitivity is listed as an adverse effect; prudent sun protection is reasonable.
| Reason for Discontinuation | Approximate Frequency | Context |
|---|---|---|
| Persistent hypokalemia / muscle cramps | Common at higher doses | Strongly dose-dependent. Often manageable by reducing dose to 1.25 mg or adding ACEi/ARB |
| Hyponatremia (esp. older women) | Common in elderly | Specific labeled warning. Reduces with use of 1.25 mg dose |
| Gout flare | Uncommon | Switching to losartan, ACEi, or CCB is reasonable |
| Erectile dysfunction | Uncommon | Often cited as a quality-of-life reason; class switch usually resolves |
Indapamide’s adverse-effect profile is unusually well-quantified by dose. The FDA label provides explicit numbers: at 1.25 mg, hypokalemia is largely a laboratory finding (20% lab vs 2% symptomatic), and severe hyponatremia was not seen in trials. At 5 mg, hypokalemia rises to 61% (lab) and 7% (symptomatic), and severe hyponatremia has been reported. Mitigation is structured: confirm a baseline electrolyte panel before starting; recheck within 2–4 weeks, then at 3–6 months and after any dose increase or addition of an interacting drug. Stay at the lowest effective dose. Pair routinely with an ACEi, ARB, or potassium-sparing diuretic in patients prone to hypokalemia. Counsel patients to report dizziness, lightheadedness, muscle cramps, or confusion early — particularly older women, who are at the highest risk of severe hyponatremia.
Drug Interactions
Indapamide is extensively hepatically metabolized but is not a significant CYP inhibitor or inducer at clinical doses. The most clinically meaningful interactions are pharmacodynamic — driven by additive electrolyte effects, additive blood-pressure effects, or interference with renal handling of co-administered drugs. The current FDA indapamide label specifically lists three interactions in the Drug Interactions section: lithium (cross-referenced to Warnings), other antihypertensives, and norepinephrine. Additional interactions below are well-established class effects from clinical-pharmacology references and major interaction databases (Lexicomp, Medscape).
Monitoring
-
Serum Electrolytes (K⁺, Na⁺, Cl⁻, HCO₃⁻, Mg²⁺, Ca²⁺)
Baseline → 2–4 weeks → 3–6 months → annually
Routine FDA label requires periodic determinations of serum electrolytes at appropriate intervals. Hypokalemia and hyponatremia drive most clinically meaningful events. Older women on 2.5 mg or 5 mg are at the highest risk for severe hyponatremia. Recheck within 1–2 weeks of dose change, intercurrent illness, or addition of corticosteroid, NSAID, or laxative. -
Serum Creatinine / BUN / eGFR
Baseline → with each electrolyte panel
Routine FDA label states renal function tests should be performed periodically during treatment with indapamide. A clinically significant decline should prompt withholding or discontinuation. Mean BUN increase ~1.46 mg/dL at 1.25 mg per FDA label. -
Blood Pressure
Baseline → 4 weeks → quarterly until stable, then annually
Routine Allow 4 weeks for full BP response before titrating per FDA label. Home BP monitoring is particularly useful with indapamide because of its smooth 24-hour effect. -
Uric Acid
Baseline → annually; or sooner if gout history
Routine (FDA label calls for periodic measurement) Per FDA label, serum concentrations of uric acid should be monitored periodically during treatment. Mean rise +0.69 mg/dL at 1.25 mg, +1 mg/dL at higher doses. -
Glucose / HbA1c
Baseline → 3 months → annually
Routine (FDA label) Per FDA label, serum concentrations of glucose should be monitored routinely during treatment with indapamide. Mean rise +6.47 mg/dL at 1.25 mg. Higher surveillance in prediabetes or metabolic syndrome. -
Skin Examination
Annually; sooner if new lesion or fair skin
Prudent (not FDA-required for indapamide) Unlike HCTZ, indapamide does not carry a US FDA labeling change for non-melanoma skin cancer; however, photosensitivity is listed in the label, and prudent sun protection is reasonable. Watch for new growths in patients with prior NMSC or fair skin. -
Lithium level
During concomitant use; recheck after any indapamide dose change
Trigger-based (FDA Warning) FDA label states diuretics should not be given concomitantly with lithium given the high risk of toxicity. If unavoidable, frequent lithium-level monitoring is required. -
Ophthalmology assessment
If new visual symptoms or eye pain
Trigger-based Acute myopia and angle-closure glaucoma usually present within hours to weeks of starting therapy and require immediate discontinuation per FDA label. -
ECG (in QT-risk populations)
If on QT-prolonging drugs or with cardiac arrhythmias
Trigger-based The FDA label specifically calls for caution in patients on cardiac glycosides or with arrhythmias. Indapamide-induced hypokalemia is the QT-prolongation mechanism.
For uncomplicated hypertension on indapamide 1.25 mg: baseline electrolytes, creatinine, glucose, uric acid; recheck electrolytes and creatinine at 2–4 weeks, then at 3–6 months, and annually thereafter. Add an interval check after any dose change, hospitalisation, or addition of an interacting drug. Older women warrant tighter surveillance for hyponatremia. Patients on cardiac glycosides or QT-prolonging drugs warrant tight K⁺ and Mg²⁺ control.
Contraindications & Cautions
Absolute Contraindications (FDA Label)
- Anuria.
- Known hypersensitivity to indapamide or to other sulfonamide-derived drugs. Cross-reactivity between antibiotic sulfonamides and non-antibiotic sulfonamides such as indapamide is uncertain; clinical-pharmacology references note that the cross-reactivity may be low, but the FDA label retains the broad contraindication.
Relative Contraindications (Specialist Input or Class Change Recommended)
- Severe renal impairment (eGFR <30 mL/min/1.73 m²) — indapamide may exacerbate or precipitate azotemia per FDA label; loop diuretic generally preferred for edema. May still be added to a loop diuretic in resistant edema (specialist setting).
- Advanced hepatic impairment / decompensated cirrhosis / hepatic encephalopathy — minor fluid and electrolyte shifts can precipitate hepatic coma per FDA label; monitor mental status closely or avoid.
- Severe hyponatremia or refractory hypokalemia at baseline — correct first; investigate cause. The FDA label warns about both as labeled adverse events.
- Concomitant lithium therapy — FDA label states diuretics should not be given concomitantly with lithium because of the high risk of toxicity.
- Active gout — consider losartan, ACEi, or CCB as alternative antihypertensive.
- Pregnancy — FDA label warns that routine use of diuretics in healthy pregnant women is inappropriate; use only if clearly needed (e.g., pathologic edema). Risk of fetal/neonatal jaundice, thrombocytopenia, electrolyte abnormalities.
- Lactation — FDA label states that if treatment is essential, the patient should stop nursing.
- Pediatric patients — safety and effectiveness not established per FDA label.
- Concomitant Class III antiarrhythmics or strong QT-prolonging drugs — additive QT prolongation through hypokalemia; avoid where possible.
Use with Caution
- Older adults, particularly older women — heightened risk of severe hyponatremia (specifically labeled by FDA as occurring “primarily in elderly females”).
- Diabetes mellitus — may affect glycemic control; the FDA label notes that latent diabetes may become manifest and insulin requirements may be altered.
- Patients on cardiac glycosides (digoxin) — hypokalemia sensitizes the myocardium per FDA label.
- Patients on QT-prolonging drugs — maintain potassium and magnesium tightly.
- Volume-depleted patients — heightens AKI and orthostatic risk; rehydrate before initiation.
- Hypercalcemic states — indapamide can elevate serum calcium with chronic use; discontinue before tests of parathyroid function.
- Patients with sulfonamide or penicillin allergy — modestly elevated risk for acute angle-closure glaucoma and acute myopia per FDA label.
- Pre-existing systemic lupus erythematosus — thiazide-class agents have exacerbated SLE; the FDA label states this possibility should be considered with indapamide.
Indapamide does not carry a boxed warning. The principal labeled warnings are: (1) Severe hyponatremia accompanied by hypokalemia — reported with recommended doses, primarily in elderly females, and dose-related; severe hyponatremia (Na⁺ <125 mEq/L) was not observed at the 1.25 mg dose in clinical trials but has been identified at 2.5 mg and 5 mg in pharmacoepidemiology. (2) Hypokalemia — common with diuretics; electrolyte monitoring is essential, particularly in patients with cardiac arrhythmias or on cardiac glycosides. (3) Lithium — diuretics should not be given concomitantly with lithium because they reduce its renal clearance and add a high risk of lithium toxicity.
Patients should be started at the 1.25 mg dose and maintained at the lowest possible dose. Note that the August 2020 FDA labeling change adding non-melanoma skin cancer risk to hydrochlorothiazide has not been extended to indapamide in current US labels.
Patient Counselling
Purpose of Therapy
Indapamide is a “water tablet” used to lower blood pressure or remove excess fluid in heart failure. It works gradually over about four weeks to reduce the workload on the heart and arteries — so patients should not expect to feel the medication doing anything. Lowering blood pressure protects against stroke, heart attack, kidney damage, and heart failure over the long term. Indapamide was the diuretic in landmark trials in older adults (HYVET) and in patients with prior stroke or diabetes (PROGRESS, ADVANCE), so it has a strong evidence base for outcome prevention. Its long action means a single morning dose covers 24 hours.
How to Take
Take the tablet once daily in the morning, so the increased urination occurs during the day rather than at night. The medication can be taken with or without food. If a dose is missed, take it as soon as remembered the same day; if it is nearly time for the next dose, skip the missed dose entirely — never double up. Do not stop the medication without speaking with the prescribing clinician, even if blood pressure feels normal. Blood tests for potassium, sodium, kidney function, and (later) glucose and uric acid are part of the prescription; missing them is not optional.
Sources
- U.S. Food and Drug Administration / DailyMed. Indapamide Tablets, USP — Prescribing Information. Actavis Pharma / Teva Pharmaceuticals. Revised October 2022. dailymed.nlm.nih.gov Current US prescribing information for generic indapamide; primary source for indications, dosing, contraindications, warnings, adverse-event incidence data, and pharmacokinetic parameters cited in this monograph.
- U.S. Food and Drug Administration. Lozol® (indapamide) 1.25 mg tablets — Prescribing Information (historical reference). Revised July 2005. accessdata.fda.gov Original innovator label (Lozol now discontinued in the US); content largely unchanged in current generic labels.
- European/UK reference: Servier. Natrilix SR® (indapamide hemihydrate) 1.5 mg prolonged-release tablets — Summary of Product Characteristics. Available via national medicines agencies (e.g., emc.medicines.org.uk). European reference for the 1.5 mg sustained-release formulation used in HYVET, PROGRESS, and ADVANCE; not approved in the US.
- Beckett NS, Peters R, Fletcher AE, et al; HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358(18):1887–1898. doi.org/10.1056/NEJMoa0801369 Landmark RCT of indapamide SR 1.5 mg ± perindopril in 3,845 patients ≥80 years; reduced fatal stroke 39% (p=0.046), all-cause mortality 21% (p=0.019), and heart failure 64% (p<0.0001). The primary endpoint of all stroke (30% reduction) did not reach statistical significance. Stopped early due to mortality benefit.
- PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358(9287):1033–1041. doi.org/10.1016/S0140-6736(01)06178-5 Active treatment reduced overall stroke recurrence 28% (95% CI 17–38, p<0.0001). Combination perindopril plus indapamide reduced stroke 43% (95% CI 30–54); perindopril alone produced no significant reduction.
- Patel A, MacMahon S, Chalmers J, et al; ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370(9590):829–840. doi.org/10.1016/S0140-6736(07)61303-8 11,140 patients with type 2 diabetes randomized to perindopril/indapamide or placebo. Primary composite (major macrovascular or microvascular event) reduced 9% (HR 0.91; 95% CI 0.83–1.00; p=0.04); all-cause mortality reduced 14% (7.3% vs 8.5%; HR 0.86; p=0.03); CV mortality reduced 18% (3.8% vs 4.6%; p=0.03).
- Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Hypertension. 2018;71(6):e13–e115. doi.org/10.1161/HYP.0000000000000065 Recommends thiazide-like diuretics (chlorthalidone, indapamide) as preferred over hydrochlorothiazide for hypertension based on cardiovascular outcome evidence and prolonged half-life.
- Mancia G, Kreutz R, Brunström M, et al. 2023 ESH Guidelines for the management of arterial hypertension. J Hypertens. 2023;41(12):1874–2071. doi.org/10.1097/HJH.0000000000003480 European hypertension guideline endorsing thiazide-like diuretics (indapamide, chlorthalidone) among preferred initial therapies.
- Ernst ME, Fravel MA. Thiazide and the thiazide-like diuretics: review of hydrochlorothiazide, chlorthalidone, and indapamide. Am J Hypertens. 2022;35(7):573–586. doi.org/10.1093/ajh/hpac048 Comprehensive comparative review covering pharmacology, dosing, and outcome data for the three principal thiazide-class agents.
- Olde Engberink RHG, Frenkel WJ, van den Bogaard B, et al. Effects of thiazide-type and thiazide-like diuretics on cardiovascular events and mortality: systematic review and meta-analysis. Hypertension. 2015;65(5):1033–1040. doi.org/10.1161/HYPERTENSIONAHA.114.05122 Meta-analysis suggesting thiazide-like agents (indapamide, chlorthalidone) reduce CV events and HF more than thiazide-type diuretics (HCTZ).
- Roush GC, Ernst ME, Kostis JB, Tandon S, Sica DA. Head-to-head comparisons of hydrochlorothiazide with indapamide and chlorthalidone: antihypertensive and metabolic effects. Hypertension. 2015;65(5):1041–1046. doi.org/10.1161/HYPERTENSIONAHA.114.05021 Comparative effectiveness analysis supporting indapamide and chlorthalidone over HCTZ for BP lowering at typical clinical doses.
- Liamis G, Filippatos TD, Elisaf MS. Thiazide-associated hyponatremia in the elderly: what the clinician needs to know. J Geriatr Cardiol. 2017;14(1):73–82. doi.org/10.11909/j.issn.1671-5411.2017.01.003 Practical framework for identifying and managing thiazide-induced hyponatremia in older adults — relevant to indapamide’s specific labeled warning about hyponatremia in elderly females.
- Pottegård A, Hallas J, Olesen M, et al. Hydrochlorothiazide use is strongly associated with risk of lip cancer. J Intern Med. 2017;282(4):322–331. doi.org/10.1111/joim.12629 Provides context for the class-effect skin cancer concern; chlorthalidone and indapamide were not specifically implicated in this analysis, supporting the FDA’s decision to limit the 2020 NMSC labeling change to HCTZ alone.